I-MAB SPONS.ADS/1 -0001 (0VY) - Total Liabilities

Latest as of December 2025: €29.58 Million EUR ≈ $34.58 Million USD

Based on the latest financial reports, I-MAB SPONS.ADS/1 -0001 (0VY) has total liabilities worth €29.58 Million EUR (≈ $34.58 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore I-MAB SPONS.ADS/1 -0001 long-term investment intensity to see how much of total assets are deployed in long-term investments.

I-MAB SPONS.ADS/1 -0001 - Total Liabilities Trend (2021–2025)

This chart illustrates how I-MAB SPONS.ADS/1 -0001's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of I-MAB SPONS.ADS/1 -0001.

I-MAB SPONS.ADS/1 -0001 Competitors by Total Liabilities

The table below lists competitors of I-MAB SPONS.ADS/1 -0001 ranked by their total liabilities.

Company	Country	Total Liabilities
Ames National Corporation NASDAQ:ATLO	USA	$1.93 Billion
Guangdong Electric Power Devel SHE:200539	China	HK$144.43 Billion
Electreon Wireless Ltd TA:ELWS	Israel	ILA23.94 Million
CB Financial Services Inc NASDAQ:CBFV	USA	$1.49 Billion
HARIM Co. Ltd KQ:136480	Korea	₩503.59 Billion
Lindsay Australia Ltd AU:LAU	Australia	AU$565.43 Million
Tatung System Technologies TWO:8099	Taiwan	NT$1.92 Billion
Inversora Juramento SA BA:INVJ	Argentina	AR$215.50 Billion

Liability Composition Analysis (2021–2025)

This chart breaks down I-MAB SPONS.ADS/1 -0001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See I-MAB SPONS.ADS/1 -0001 net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	8.09	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.13	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.11	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how I-MAB SPONS.ADS/1 -0001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for I-MAB SPONS.ADS/1 -0001 (2021–2025)

The table below shows the annual total liabilities of I-MAB SPONS.ADS/1 -0001 from 2021 to 2025.

Year	Total Liabilities	Change
2025-12-31	€29.58 Million ≈ $34.58 Million	+156.78%
2024-12-31	€11.52 Million ≈ $13.47 Million	-90.88%
2023-12-31	€126.34 Million ≈ $147.70 Million	-25.10%
2022-12-31	€168.68 Million ≈ $197.20 Million	+3.22%
2021-12-31	€163.42 Million ≈ $191.05 Million	--

About I-MAB SPONS.ADS/1 -0001

F:0VY Germany Biotechnology

Market Cap

$189.29 Million

€161.91 Million EUR

Market Cap Rank

#16850 Global

#1587 in Germany

Share Price

€1.40

Change (1 day)

+2.94%

52-Week Range

€1.25 - €5.60

All Time High

€70.00